💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tizanidine

CHEMBL1079 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
253.7 g/mol
LogP
1.1
Phase
4

This muscle relaxant is used to manage muscle spasticity — the tightening or stiffening of muscles — caused by conditions such as multiple sclerosis or spinal cord injury. It works by blocking nerve signals in the brain and spinal cord that trigger muscle contractions. It can cause significant drowsiness and a drop in blood pressure, especially when first starting treatment.

分子量

253.7100 g/mol

LogP

1.10

TPSA

90.40 Ų

リピンスキーの五則

適合

治療領域

Pain Management Rheumatoid Arthritis Migraine Insomnia Melanoma Multiple Sclerosis Stroke Gout Chronic Pain

作用機序

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Clc1ccc2nsnc2c1NC1=NCCN1

                

                

                
                

                    
InChI

                    
InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)

                

                

                

                    
                    

                        
Molecular Formula

                        
C9H8ClN5S

                    

                    
                    

                        
HBD / HBA

                        
2 / 4

                    

                    
                    

                        
回転可能結合数

                        
2

                    

                    
                    
                    

                        
重原子数

                        
16

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
This muscle relaxant is used to manage muscle spasticity — the tightening or stiffening of muscles — caused by conditions such as multiple sclerosis or spinal cord injury. It works by blocking nerve signals in the brain and spinal cord that trigger muscle contractions. It can cause significant drowsiness and a drop in blood pressure, especially when first starting treatment.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Tizanidine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1079.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5487.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.